Markets
markets
Luke Kawa

There’s a full-blown meltdown in the AI boom’s supporting cast of speculative, volatile stocks

Nvidia’s results weren’t good enough to help the chip designer, but the reaction has been so much worse for other parts of the AI trade. The meltdown in the AI boom’s supporting cast of more speculative, volatile stocks is deepening sharply on Friday:

  • Bitcoin miners turned data center providers Cipher Digital and IREN are in a world where the market seems to have soured on everything they’re associated with. Shares of both have tumbled more than 7% on the day.

  • Neoclouds CoreWeave and Nebius are both off about 5% or more. The former is now 66% off its record closing high, while the latter is in a 40% drawdown.

  • Nuclear energy firm Oklo is down 8%, and has lost over half its value since mid-October. Its trailing price-to-sales ratio remains aggressively unchanged through this rout (because it is a zero-revenues company).

  • The Bloom (Energy) is off the rose, with the fuel cell company off more than 40% from its peak. Shares of Bloom Energy are cratering amid bearish options activity, with its put/call ratio at a four-month high as of 10:55 a.m. ET.

The rollover in these speculative pockets of the market (as well as bitcoin!) starting in October seems to have presaged the current bout of pain for major US indexes.

To repeat myself, when the question of, “Oracle will be able to pay me back, right?” enters your mind, that’s probably not consistent with a world where smaller companies on the outskirts of the AI ecosystem can continuously be bid up to the moon.

More Markets

See all Markets
markets

Allbirds traded more than JPMorgan and Exxon Mobil yesterday

After a surprising announcement that the tech-bro shoemaker would be pivoting to AI on Wednesday, shares of Allbirds were flying high — soaring nearly 600% by the end of the day in record trading volume.

This was, for many reasons, completely insane.

Flipping the BIRD

Before the latest pop, Allbirds had a miniscule market cap of some ~$22 million. Yesterday, some $3.8 billion changed hands in BIRD — with the company's market cap ending the session at a still-small $148 million.

That means that the company turned over more than 25x its market cap in trading volume. Indeed, there were no other stocks with a market cap less than $1 billion that traded more than $1 billion yesterday — something of an outlier, to say the least.

Allbirds trading volume
Sherwood News

Two of the stocks that Allbirds out-traded were none other than the world's largest bank (JPMorgan), and America's largest oil company (Exxon Mobil), which only turned over $3 billion and $2.3 billion, respectively. And those weren't even particularly low-volume days for those two corporate giants — Allbirds' insane activity was way ahead of the average of the last 120 days for each.

Sole searching

Although this was perhaps more of a meme-stock story than an AI story, those two worlds are becoming to overlap, as retail traders have bought up anything adjacent to AI — particularly in the last couple of weeks as risk-on assets have ripped higher since geopolitical risks have (seemingly) abated and indices are back to all-time highs.

Of course, we've seen this movie before: remember Algorhythm Holdings, a former karaoke maker turned AI trucking logistics company, which obliterated the freight industry only a few months ago? Then there was the Long Island Iced Tea Corp., which, naturally, got into the blockchain.

Allbirds’ latest pivot, with a “long-term vision to become a fully integrated GPU-as-a-Service (GPUaaS) and AI-native cloud solutions provider” which will be funded with its new $50 million convertible financing facility, is unlikely to concern neocloud leaders like CoreWeave, which is planning to spend $30 billion in 2026.

markets

Hims jumps after RFK Jr. announces FDA may loosen regulations for 12 peptides

Hims & Hers rose more than 13% on Wednesday and continued to rise in premarket trading on Thursday after Health Secretary Robert F. Kennedy Jr. said that the Food and Drug Administration could ease restrictions on 12 peptides.

The move would allow compounding pharmacies to dispense the list of peptides, which have grown in popularity but are currently only available through suppliers who sell them for research purposes.

Hims and other consumer health companies have positioned themselves to begin selling peptides after getting the FDA nod.

Hims and other consumer health companies have positioned themselves to begin selling peptides after getting the FDA nod.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.